Clinical Trials Browser

Phase 3 × polatuzumab vedotin × 1 year × Clear all

NCT03274492 2026-05-08

POLARIX

Phase 3 Completed

1,000 enrolled 1 FDA

Lymphoma, Large B-Cell, Diffuse

NCT05171647 2026-05-07

SUNMO

Phase 3 Active not recruiting

208 enrolled 12 charts

Lymphoma, Non-Hodgkin

NCT04182204 2025-12-22

POLARGO

Phase 3 Completed

270 enrolled 36 charts

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT04833114 2025-09-30

Pola-R-ICE

Phase 3 Active not recruiting

Lymphoma, Large B-Cell, Diffuse